Showing 7541-7550 of 9496 results for "".
- Dermalogica Launches New Course on Treating Melanin-Rich Skinhttps://practicaldermatology.com/news/dermalogica-launches-new-course-on-treating-melanin-rich-skin/2461545/In a move to address under-representation in the professional skin care industry’s training curricula regarding melanin-rich skin tones (specifically those categorized as Fitzpatrick levels IV-VI), Dermalogica announced it is launching “Treating Melanin-Rich Skin.” <
- Escient Pharmaceuticals Receives FDA IND Clearance to Start Phase 1 Study of EP262https://practicaldermatology.com/news/escient-pharmaceuticals-receives-fda-ind-clearance-to-start-phase-1-study-of-ep262/2461542/The FDA has cleared Escient Pharmaceuticals’ investigational new drug (IND) application for EP262. The clearance allows the Escient to initiate a Phase 1 first-in-human study for the company’s second drug candidate to be advanced into clinical development. EP262 is a first-i
- In Phase 2b Trial, Spesolimab Meets Endpoints for Prevention of Generalized Pustular Psoriasis (GPP) Flareshttps://practicaldermatology.com/news/in-phase-2b-trial-spesolimab-meets-endpoints-for-prevention-of-generalized-pustular-psoriasis-gpp-flares/2461529/Spesolimab (Boehringer Ingelheim), an anti-interleukin-36 receptor antibody, met its primary and key secondary endpoint, demonstrating it can prevent flares in patients with generalized pustular psoriasis (GPP) and provide sustained symptom management up to 48 weeks, according to results of the P
- Phase 2 Data: Jeuveau “Extra-Strength” Dose Produces Lasting Resultshttps://practicaldermatology.com/news/phase-2-data-jeuveau-extra-strength-dose-produces-lasting-results/2461528/Evolus' Jeuveau Extra-Strength achieved one-point improvement on the Glabellar Lines Scale with the duration of effect lasting 26 weeks, representing a prolonged 6-month performance, the Company reports. The extra-strength glabellar line study is a multicenter, double
- Meet FACE by Galdermahttps://practicaldermatology.com/news/meet-face-by-galderma/2461524/Galderma is launching FACE by Galderma, an app that simulates the results of injectable treatments in real time using digital facial assessment. The technology was unveiled at the International Master Course on Aging Science (IMCAS) World Congress 2023 in Paris. FACE by Galder
- Bristol Myers Squibb Receives Positive CHMP Opinion for Once-Daily Sotyktu as Plaque Psoriasis Treatmenthttps://practicaldermatology.com/news/bristol-myers-squibb-receives-positive-chmp-opinion-for-once-daily-sotyktu-as-plaque-psoriasis-treatment/2461522/Four months after receiving FDA approval, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended the approval of Sotyktu (deucravacitinib; Bristol Myers Squibb) for the treatment of adults with moderate-to-severe plaque psoriasis. 
- University of Missouri-Columbia-Developed Teledermatology Program Improves Diagnosis of Skin Conditions in Underserved Communitieshttps://practicaldermatology.com/news/university-of-missouri-columbia-developed-teledermatology-program-improves-diagnosis-of-skin-conditions-in-underserved-communities/2461517/A teledermatology program first developed by the University of Missouri in 2015 can help improve the diagnoses of skin conditions in underserved communities, according to a new study in Journal of Telemedicine
- Revealed: The Genetic Basis of 13 Pigment Traits and Their Relationship with Diseaseshttps://practicaldermatology.com/news/revealed-the-genetic-basis-of-13-pigment-traits-and-their-relationship-with-diseases/2461515/Researchers have uncovered the genetic basis of 13 pigment traits and their association with diseases. Using the GCAT cohort, researchers built a comprehensive analysis strategy leading to the identification of phototype associated-diseases in a total of nearly 20,000 Ca
- Update: Two More Payers to Cover DermTech’s Melanoma Testhttps://practicaldermatology.com/news/update-two-more-payers-to-cover-dermtechs-melanoma-test/2461514/Two new payers plan to cover the DermTech Melanoma Test, making the foundational assay available to approximately 1.2 million more people. The new insurers are Blues plan in Hawaii and a physician-founded, member-focused and community-based not-for-profit health plan in New York. T
- Twenty New Products Earn NPF Seal of Recognitionhttps://practicaldermatology.com/news/twenty-new-products-earn-npf-seal-of-recognition/2461512/Twenty new products have earned the National Psoriasis Foundation’s Seal of Recognition. Each of these 20 products passed the same rigorous application, review, and approval process as the other 45 products that comprise the